Tezepelumab is a fully human anti-TSLP mAb that prevents interaction of TSLP with its receptor, thereby inhibiting downstream inflammatory pathways; tezepelumab has been used for the treatment of severe asthma in phase II trials (151). The gene discussed is TSLP; the disease is asthma.